Washington University Physicians have performed more than 7,500 stem cell transplants since 1982.
Siteman is a leader in unrelated donor transplants. The procedure has been offered since 1992 and we perform close to 100 every year, which is one of the highest rates in the world.
Siteman is one of only three institutions nationwide to hold a SPORE grant in leukemia.
At any given time, Siteman has more than 60 clinical trials underway for patients with leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and other diseases of the blood. Some of these trials are specific to transplant patients.
Our physicians and researchers have been involved in landmark studies investigating novel immunotherapies, including CAR-T cell therapy.
In 2008, Timothy Ley, MD; Elaine Mardis, PhD; and Richard Wilson, PhD, working in conjunction with many colleagues at The Genome Center and Siteman Cancer Center, were the first in history to sequence the DNA of a patient’s cancer, a case of acute myeloid leukemia. Their work helped usher in a new era of precision cancer treatment, in which a patient’s genes and genetic mutations guide decisions about his or her care.
Li Ding, PhD, and colleagues from the McDonnell Genome Institute were among the first to describe Clonal Hematopoiesis of Indeterminate Prognosis (CHiP) during aging.
In 2012, Li Ding, PhD; John DiPersio, MD, PhD; Timothy Ley, MD; Peter Westervelt, MD, PhD; Matthew Walter, MD; Daniel Link, MD; Timothy Graubert, MD; and John Welch MD, PhD, were the first to identify and track the subclonal architecture of AML using deep digital NextGen Sequencing.
Matthew Walter, MD; Daniel Link, MD; Timothy Ley, MD, and colleagues were among the first to use NextGen sequencing to assess risk of recurrence of AML and MDS after standard therapy and allogeneic transplant using clearance of mutations using standard and error corrected NextGen sequencing.
Matthew Christopher, MD, PhD; Michael Rettig, PhD; and John DiPersio, MD, PhD, and colleagues were the first to demonstrate that relapse of AML after allogeneic transplant is frequently associated with epigenetic silencing of HLA Class II expression on AML blasts.
Jaebok Choi, PhD, and John DiPersio, MD, PhD, defined the role of JAK1/2 signaling in GvHD. Their preclinical work and early clinical trials played a major role in the recent FDA approval of Jakafi for the treatment of steroid refractory GvHD.